{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:35:36Z","timestamp":1774647336395,"version":"3.50.1"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,8,20]]},"abstract":"<jats:p>ATI-2173 is a novel liver-targeted molecule designed to deliver the 5\u2032-monophosphate of clevudine for the treatment of chronic hepatitis B infection. Unlike other nucleos(t)ides, the active clevudine-5\u2032-triphosphate is a noncompetitive, non-chain-terminating inhibitor of hepatitis B virus (HBV) polymerase that delivers prolonged reduction of viremia in both a woodchuck HBV model and in humans for up to 6 months after cessation of treatment. However, long-term clevudine treatment was found to exhibit reversible skeletal myopathy in a small subset of patients and was subsequently discontinued from development.<\/jats:p>","DOI":"10.1128\/aac.00836-20","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T14:15:17Z","timestamp":1591884917000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":24,"title":["ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens"],"prefix":"10.1128","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9502-9361","authenticated-orcid":false,"given":"Katherine E.","family":"Squires","sequence":"first","affiliation":[{"name":"Antios Therapeutics, Inc., Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas L.","family":"Mayers","sequence":"additional","affiliation":[{"name":"Antios Therapeutics, Inc., Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R.","family":"Bluemling","sequence":"additional","affiliation":[{"name":"Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA"},{"name":"Drug Innovation Ventures at Emory (DRIVE), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Kolykhalov","sequence":"additional","affiliation":[{"name":"Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Guthrie","sequence":"additional","affiliation":[{"name":"Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhakar","family":"Reddy","sequence":"additional","affiliation":[{"name":"Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie G.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manohar T.","family":"Saindane","sequence":"additional","affiliation":[{"name":"Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary M.","family":"Sticher","sequence":"additional","affiliation":[{"name":"Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vindhya","family":"Edpuganti","sequence":"additional","affiliation":[{"name":"Emory Institute for Drug Development (EIDD), Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abel","family":"De La Rosa","sequence":"additional","affiliation":[{"name":"Antios Therapeutics, Inc., Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.12.061"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270628"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02066-09"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29323"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2015.21.1.1"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.20899"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20257"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21166"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03686.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21629"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21800"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.06.011"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.019"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22959"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.380"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00109-11"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00599-13"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(96)00049-4"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.161802"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.7b00148"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp060070y"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.833"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.39.4.979"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1541"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/135965350801300206","article-title":"Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes","volume":"13","author":"Niu C","year":"2008","unstructured":"Niu C, Murakami E, Furman PA. 2008. Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Antivir Ther 13:263\u2013269.","journal-title":"Antivir Ther"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24318"},{"key":"e_1_3_3_29_2","first-page":"9630","article-title":"Detection and analysis of resistance mutations of hepatitis B virus","volume":"8","author":"He X","year":"2015","unstructured":"He X, Wang F, Huang B, Chen P, Zhong L. 2015. Detection and analysis of resistance mutations of hepatitis B virus. Int J Clin Exp Med 8:9630\u20139639.","journal-title":"Int J Clin Exp Med"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.13173"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01061-09"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21698"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep42374"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.11.036"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.027"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-044450986-4\/50075-8"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21294"},{"key":"e_1_3_3_38_2","first-page":"5211","article-title":"Preliminary report of hepatitis B virus genotype prevalence in Iran","volume":"12","author":"Alavian SM","year":"2006","unstructured":"Alavian SM, Keyvani H, Rezai M, Ashayeri N, Sadeghi HM. 2006. Preliminary report of hepatitis B virus genotype prevalence in Iran. World J Gastroenterol 12:5211\u20135213.","journal-title":"World J Gastroenterol"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.200"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-004-3010-7"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2018.12027892"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2007.00102.x"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021436"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-014-9537-5"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl15562"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058843"},{"key":"e_1_3_3_47_2","unstructured":"Antios Therapeutics Inc. 2020. A phase 1 double-blinded study for safety tolerability pharmacokinetics and antiviral activity of ATI-2173 in healthy subjects and subjects with chronic hepatitis B virus infection. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04248426."},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(90)90001-N"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00836-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00836-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T21:58:28Z","timestamp":1666907908000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00836-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8,20]]}},"alternative-id":["10.1128\/AAC.00836-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.00836-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"2020-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00836-20"}}